MX2023015183A - Biomarcadores para el tratamiento de la enfermedad de alzheimer. - Google Patents
Biomarcadores para el tratamiento de la enfermedad de alzheimer.Info
- Publication number
- MX2023015183A MX2023015183A MX2023015183A MX2023015183A MX2023015183A MX 2023015183 A MX2023015183 A MX 2023015183A MX 2023015183 A MX2023015183 A MX 2023015183A MX 2023015183 A MX2023015183 A MX 2023015183A MX 2023015183 A MX2023015183 A MX 2023015183A
- Authority
- MX
- Mexico
- Prior art keywords
- alzheimer
- biomarkers
- disease treatment
- disease
- suspected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163220434P | 2021-07-09 | 2021-07-09 | |
| US202163203444P | 2021-07-22 | 2021-07-22 | |
| US202163263255P | 2021-10-29 | 2021-10-29 | |
| US202163263928P | 2021-11-11 | 2021-11-11 | |
| US202163264551P | 2021-11-24 | 2021-11-24 | |
| US202263306028P | 2022-02-02 | 2022-02-02 | |
| US202263269372P | 2022-03-15 | 2022-03-15 | |
| US202263364618P | 2022-05-12 | 2022-05-12 | |
| PCT/US2022/073576 WO2023283650A1 (en) | 2021-07-09 | 2022-07-08 | Biomarkers for alzheimer's disease treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023015183A true MX2023015183A (es) | 2024-03-14 |
Family
ID=83232761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023015183A MX2023015183A (es) | 2021-07-09 | 2022-07-08 | Biomarcadores para el tratamiento de la enfermedad de alzheimer. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250163135A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4367516A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024525559A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240033017A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022307687A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3225302A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2024000063A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL309468A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023015183A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202317192A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023283650A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120076808A (zh) | 2022-09-23 | 2025-05-30 | 卫材R&D管理有限公司 | 减少与神经退行性疾病相关的神经退行性变的方法 |
| WO2025019457A1 (en) * | 2023-07-15 | 2025-01-23 | Eisai R&D Management Co., Ltd. | Antimicrobial peptides |
| WO2025260029A1 (en) | 2024-06-14 | 2025-12-18 | Eisai R&D Management Co., Ltd. | Method for quantifying amyloid beta protofibril |
| CN118777453B (zh) * | 2024-06-25 | 2025-04-08 | 上海交通大学医学院附属瑞金医院 | 一种基于液相色谱-串联质谱定量分析血液中仑卡奈单抗浓度的方法 |
| WO2026015877A1 (en) | 2024-07-12 | 2026-01-15 | Eisai R&D Management Co., Ltd. | Fluid biomarker |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001268005A1 (en) | 2000-07-07 | 2002-01-21 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| MY169492A (en) | 2006-03-23 | 2019-04-15 | Bioarctic Neuroscience Ab | Improved protofibril selective antibodies and the use thereof |
| SI2448968T1 (sl) | 2009-06-29 | 2021-07-30 | Bioarctic Ab | Protitelesa, selektivna za protofibrile/oligomere na N-koncu skrajšanega amiloida-beta |
| CN110655573B (zh) | 2010-02-26 | 2023-07-18 | 生命北极神经科学公司 | 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用 |
| CN106661103B (zh) | 2014-07-10 | 2020-11-03 | 生命北极神经科学公司 | 改进的Aβ初原纤维结合抗体 |
| JP6851549B2 (ja) | 2017-10-16 | 2021-03-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗タウ抗体及びその使用 |
| PT4121007T (pt) | 2020-03-20 | 2025-09-25 | Eisai R&D Man Co Ltd | Formulações de anticorpo de protofibrila de péptido anti-beta amiloide de concentração alta e métodos de uso das mesmas |
| CA3172451A1 (en) * | 2020-04-03 | 2021-10-07 | Robert Paul | Methods of use of anti-trem2 antibodies |
| TWI843040B (zh) * | 2021-01-11 | 2024-05-21 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
-
2022
- 2022-07-08 JP JP2024500220A patent/JP2024525559A/ja active Pending
- 2022-07-08 EP EP22765973.7A patent/EP4367516A1/en active Pending
- 2022-07-08 TW TW111125802A patent/TW202317192A/zh unknown
- 2022-07-08 IL IL309468A patent/IL309468A/en unknown
- 2022-07-08 CA CA3225302A patent/CA3225302A1/en active Pending
- 2022-07-08 KR KR1020247004758A patent/KR20240033017A/ko active Pending
- 2022-07-08 US US18/577,174 patent/US20250163135A1/en active Pending
- 2022-07-08 MX MX2023015183A patent/MX2023015183A/es unknown
- 2022-07-08 AU AU2022307687A patent/AU2022307687A1/en active Pending
- 2022-07-08 WO PCT/US2022/073576 patent/WO2023283650A1/en not_active Ceased
-
2024
- 2024-01-08 CL CL2024000063A patent/CL2024000063A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023283650A1 (en) | 2023-01-12 |
| IL309468A (en) | 2024-02-01 |
| CL2024000063A1 (es) | 2024-08-02 |
| JP2024525559A (ja) | 2024-07-12 |
| CA3225302A1 (en) | 2023-01-12 |
| US20250163135A1 (en) | 2025-05-22 |
| EP4367516A1 (en) | 2024-05-15 |
| KR20240033017A (ko) | 2024-03-12 |
| TW202317192A (zh) | 2023-05-01 |
| AU2022307687A1 (en) | 2024-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024000063A1 (es) | Biomarcadores para el tratamiento de la enfermedad de alzheimer | |
| CL2024002309A1 (es) | Métodos de tratamiento usando nivel de p-tau181. | |
| MX2025005880A (es) | Metodos de tratamiento que usan un nivel de tomografia de emision de positrones (pet) de tau | |
| CL2020000343A1 (es) | Métodos y materiales para evaluar y tratar el cáncer. | |
| WO2015157407A8 (en) | Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment | |
| BRPI0720035A2 (pt) | métodos para tratar um paciente tendo uma doença ou distúrbio, para tratar um paciente com doença autoimune, para neutralizar um perfil de expressão do marcador pd indutível por ifn do tipo 1 ou ifnalfa em um paciente, para monitorar ou prognosticar progressão de doença autoimune de um paciente, para monitorar a progressão da doença de um paciente que recebe o tratamento com um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para identificar um paciente como um candidato para um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para diagnosticar um paciente como tendo um distùrbio associado com níveis aumentados de ifnalfa, para identificar um terapêutico candidato para o tratamento de distùrbios mediados por ifnalfa e para detectar atividade de ifn em uma amostra, conjunto de sondas, e, kit | |
| CY1118660T1 (el) | Συνθεσεις και μεθοδοι για την θεραπεια διαταραχων ματιων | |
| CY1118566T1 (el) | Διαγνωση με χρηση ιντερφερονης τυπου 1 | |
| MX2020011458A (es) | Metodos de diagnostico y tratamiento basados en fosforilacion de tau especifica del sitio. | |
| EA200901550A1 (ru) | Способы лечения, диагностирования и выявления ассоциированных с fgf21 нарушений | |
| MX2019009986A (es) | Deteccion temprana de la activacion de celulas gliales en enfermedades neurodegenerativas o neuroinflamatorias. | |
| Ally et al. | Preserved frontal memorial processing for pictures in patients with mild cognitive impairment | |
| CR8230A (es) | Sondas para enfermedades en las cuales se acumula amiloide, agentes para tincion del amiloide, farmacos para tratamiento y profilaxis de enfermedades con amiloide acumulado y sondas para diagnostico de ovillos neuro fibrilares yagentes... | |
| WO2007041245A3 (en) | Biomarkers for multiple sclerosis and methods of use thereof | |
| EP4257705A3 (en) | Biomarkers of traumatic brain injury | |
| EP1463531A4 (en) | PROCESS FOR INHIBITING OKULAR PROCESSES | |
| BR112014031414A2 (pt) | métodos de detectar doenças ou condições utilizando células doentes circulantes | |
| AR080361A1 (es) | Identificacion, evaluacion y terapia de canceres con resistencia innata o adquirida a inhibidores de quinasa del linfoma anaplasico (alk) | |
| MX2024013120A (es) | Analisis del transcriptoma para el tratamiento de la inflamacion | |
| CL2023001600A1 (es) | Biomarcadores del agonista de trem2 y métodos para su uso | |
| CO6450654A2 (es) | Identificación de moléculas pequeñas reconocidas por anticuerpos en sujetos con enfermedades neurodegenerativas | |
| CR20230121A (es) | Tratamiento de la enfermedad de parkinson | |
| BR112018014762A2 (pt) | método de tratamento da doença de alzheimer (da) precoce | |
| Li et al. | Dynamic functional connectivity assesses the progression of Parkinson’s disease | |
| MX2018011679A (es) | Biomarcadores de proteopatias y usos de los mismos. |